Author:
Calles Antonio,Liao Xiaoyun,Sholl Lynette M.,Rodig Scott J.,Freeman Gordon J.,Butaney Mohit,Lydon Christine,Dahlberg Suzanne E.,Hodi F.Stephen,Oxnard Geoffrey R.,Jackman David M.,Jänne Pasi A.
Subject
Pulmonary and Respiratory Medicine,Oncology
Reference43 articles.
1. PD-1 and its ligands in tolerance and immunity;Keir;Annu Rev Immunol,2008
2. Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer;Sznol;Clin Cancer Res,2013
3. Incorporating immune-checkpoint inhibitors into systemic therapy of NSCLC;Champiat;J Thorac Oncol,2014
4. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer;Topalian;N Engl J Med,2012
5. An analysis of the relationship of clinical activity to baseline EGFR status, PDL1 expression and prior treatment history in patients with non-small cell lung cancer (NSCLC) following PD-L1 blockade with MPDL3280A (anti-PDL1);Horn;J Thorac Oncol,2013
Cited by
208 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献